US equities |
NVDA $237.84 ▲+1.66% SPCX $167.87 ▲+5.61% MU $1,063.50 ▼-1.06% TSLA $378.91 ▲+2.25% MSFT $525.01 ▲+1.45% SNDK $1,711.44 ▼-0.50% INTC $116.99 ▼-1.96% META $742.43 ▲+1.97%
FinancialContent

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.73 -0.10 (-0.60%)
Delayed Quote Updated: 2:10 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia to Participate in Jefferies London Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces Board Restructuring
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia to Participate in Upcoming Investor Healthcare Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces 2024 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Provides Update on Proxy Statement
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗
AUPH stock results show that Aurinia Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >